Increasing unusual call option volume: ALXN RFP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Alexion Pharmaceuticals (ALXN) PT Raised to $156 at Nomura/Instinet
March 15, 2018 1:45 PM EDTNomura/Instinet raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $156.00 (from $148.00) while maintaining a Buy rating.
Analyst Christopher Marai commented, "Alexion reported results from the P3 301 study of ALXN1210 in PNH-naïve patients. The study demonstrated non-inferiority across all co-primary and four key... More
Alexion Pharmaceuticals (ALXN) PT Raised to $160 at Baird
March 15, 2018 12:14 PM EDTBaird raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $160.00 (from $150.00) while maintaining a Outperform rating.
Analyst Michael E. Ulz commented, "Following the call, we remain encouraged by the Phase 3 PNH naïve results with ALXN1210 demonstrating non-inferiority on all six key endpoints with... More
